Catalent Inc. has wrapped up its $1.2 billion deal for Paragon Bioservices Inc., it announced Monday.
The Somerset-based provider of drug delivery technologies said in a news release that it has completed the acquisition of the Baltimore-based Paragon, a developer and manufacturer in the viral vector and gene therapy segments.
The deal gives Catalent an entry point into the market for delivering DNA to cells via gene therapy, the company said.
